Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 May 17:3:107.
doi: 10.3389/fonc.2013.00107. eCollection 2013.

Immune responses to cancer: are they potential biomarkers of prognosis?

Theresa L Whiteside  1
Affiliations

Immune responses to cancer: are they potential biomarkers of prognosis?

Theresa L Whiteside. Front Oncol. .

Abstract

Recent technical improvements in evaluations of immune cells in situ and immune monitoring of patients with cancer have provided a wealth of new data confirming that immune cells play a key role in human cancer progression. This, in turn, has revived the expectation that immune endpoints might serve as reliable biomarkers of outcome or response to therapy in cancer. The recent successes in linking the T-cell signature in human colorectal carcinoma (CRC) with prognosis have provided a strong motive for searching for additional immune biomarkers that could serve as intermediate endpoints of response to therapy and outcome in human cancers. A number of potentially promising immune biomarkers have emerged, but most remain to be validated. Among them, the B-cell signature, as exemplified by expression of the immunoglobulin G kappa chain (IGKC) in tumor-infiltrating lymphocytes (TIL), has been validated as a biomarker of response to adjuvant therapy and better survival in patients with breast carcinoma and several other types of human solid tumors. Additional immune endpoints are being currently tested as potentially promising biomarkers in cancer. In view of currently growing use of immune cancer therapies, the search for immune biomarkers of prognosis are critically important for identifying patients who would benefit the most from adjuvant immunotherapy.

Keywords: B-cell signature; T-cell signature; cancer; immune system; prognosis.

PubMed Disclaimer

References

    1. Albers A. E., Visus C., Tsukishiro T., Ferris R. L., Gooding W., Whiteside T. L., et al. (2006). Alterations in the T-cell receptor variable beta gene-restricted profile of CD8+ T lymphocytes in the peripheral circulation of patients with squamous cell carcinoma of the head and neck. Clin. Cancer Res. 12, 2394–240310.1158/1078-0432.CCR-05-1818 - DOI - PubMed
    1. Badoual C., Hans S., Rodriguez J., Peyrard S., Klein C., Agueznay Nel H., et al. (2006). Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin. Cancer Res. 12, 465–47210.1158/1078-0432.CCR-05-1886 - DOI - PubMed
    1. Bergmann C., Strauss L., Wieckowski E., Czystowska M., Albers A., Wang Y., et al. (2009). Tumor-derived microvesicles in sera of patients with head and neck cancer and their role in tumor progression. Head Neck 31, 371–38010.1002/hed.20968 - DOI - PMC - PubMed
    1. Biragyn A., Lee-Chang C. (2012). A new paradigm for an old story: the role of regulatory B cells in cancer. Front. Immunol. 3:206.10.3389/fimmu.2012.00206 - DOI - PMC - PubMed
    1. Britten C. M., Janetzki S., Van Der Burg S. H., Huber C., Kalos M., Levitsky H. I., et al. (2011). Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond. Cancer Immunol. Immunother. 60, 15–2210.1007/s00262-010-0940-z - DOI - PMC - PubMed

LinkOut - more resources